Comparison of corticosteroids types, dexamethasone, and methylprednisolone in patients hospitalized with COVID-19 : A systematic review and network meta-analysis
© 2023 Published by Elsevier Inc..
Background: COVID-19 is associated with severe pneumonia lung damage, acute respiratory distress syndrome (ARDS), and mortality. In this study, we aimed to compare corticosteroids' effect on the mortality risk in patients hospitalized with COVID-19.
Methods: PubMed, Web of Science, Scopus, Cochrane Library, and Embase, were searched using a predesigned search strategy. Randomized controlled trials (RCTs) that had compared the corticosteroid drugs were included. The hazard ratio (HR) with a 95% confidence interval (CI) was used to summarize the effect size from the network meta-analysis (NMA).
Results: Out of 329 retrieved references, 12 RCTs with 11,455 participants met the eligibility criteria in this review. The included RCTs formed one network with six treatments. In addition, five treatments in two RCTs were not connected to the network. Methylprednisolone + usual care (UC) versus UC decreased the risk of death by 0.65 (95% CI: 0.47, 0.90). Among treatments in the network the highest P-score (0.89) was related to Methylprednisolone + UC.
Conclusion: Based on the results of this NMA it seems Methylprednisolone + UC to be the best treatment option in patients with COVID-ARDS and COVID pneumonia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Global epidemiology - 6(2023) vom: 16. Dez., Seite 100116 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morsali, Mina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 19.09.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.gloepi.2023.100116 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361358350 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361358350 | ||
| 003 | DE-627 | ||
| 005 | 20231226084953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.gloepi.2023.100116 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361358350 | ||
| 035 | |a (NLM)37637717 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morsali, Mina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of corticosteroids types, dexamethasone, and methylprednisolone in patients hospitalized with COVID-19 |b A systematic review and network meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.09.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 Published by Elsevier Inc. | ||
| 520 | |a Background: COVID-19 is associated with severe pneumonia lung damage, acute respiratory distress syndrome (ARDS), and mortality. In this study, we aimed to compare corticosteroids' effect on the mortality risk in patients hospitalized with COVID-19 | ||
| 520 | |a Methods: PubMed, Web of Science, Scopus, Cochrane Library, and Embase, were searched using a predesigned search strategy. Randomized controlled trials (RCTs) that had compared the corticosteroid drugs were included. The hazard ratio (HR) with a 95% confidence interval (CI) was used to summarize the effect size from the network meta-analysis (NMA) | ||
| 520 | |a Results: Out of 329 retrieved references, 12 RCTs with 11,455 participants met the eligibility criteria in this review. The included RCTs formed one network with six treatments. In addition, five treatments in two RCTs were not connected to the network. Methylprednisolone + usual care (UC) versus UC decreased the risk of death by 0.65 (95% CI: 0.47, 0.90). Among treatments in the network the highest P-score (0.89) was related to Methylprednisolone + UC | ||
| 520 | |a Conclusion: Based on the results of this NMA it seems Methylprednisolone + UC to be the best treatment option in patients with COVID-ARDS and COVID pneumonia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Dexamethasone | |
| 650 | 4 | |a Hydrocortisone | |
| 650 | 4 | |a Methylprednisolone | |
| 650 | 4 | |a Network meta-analysis | |
| 700 | 1 | |a Doosti-Irani, Amin |e verfasserin |4 aut | |
| 700 | 1 | |a Amini, Shahideh |e verfasserin |4 aut | |
| 700 | 1 | |a Nazemipour, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Mansournia, Mohammad Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Aliannejad, Rasoul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Global epidemiology |d 2019 |g 6(2023) vom: 16. Dez., Seite 100116 |w (DE-627)NLM308778871 |x 2590-1133 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2023 |g day:16 |g month:12 |g pages:100116 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gloepi.2023.100116 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2023 |b 16 |c 12 |h 100116 | ||